美股新聞 標題聯播 · 近 24 小時 336 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · ASMB近 30 天 14 則 · 第 1 / 1 頁
- Best Momentum Stocks to Buy for September 17th
- New Strong Buy Stocks for September 17th
- Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
- Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks
- Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
- Zacks.com featured highlights include EuroDry, RCM, Assembly Biosciences, Delcath and National Energy Services
- Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High?
- Should You Buy Assembly Biosciences (ASMB) After Golden Cross?
- 5 Stocks With Recent Price Strength Buoyed by a Strong August
- Here's Why Momentum in Assembly Biosciences (ASMB) Should Keep going
- Best Momentum Stocks to Buy for August 25th
- New Strong Buy Stocks for August 25th
- Best Momentum Stocks to Buy for August 21st
- New Strong Buy Stocks for August 21st
- Are You Looking for a Top Momentum Pick? Why Assembly Biosciences (ASMB) is a Great Choice
- Wall Street Analysts Think Assembly Biosciences (ASMB) Could Surge 40.66%: Read This Before Placing a Bet
- Assembly Biosciences (ASMB) Reports Q2 Loss, Beats Revenue Estimates
- Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
- Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead
- Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands
- Assembly Biosciences (ASMB) Reports Q1 Loss, Misses Revenue Estimates
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。